Get started
Author

Atsushi Shinagawa

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 405
ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)
2003 · Norio Chikatsu, Hiroshi Kojima, et al. · Modern Pathology · 83
PDF
Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma
2020 · Tran B. Nguyen, Mamiko Sakata-Yanagimoto, et al. · Cancer Research · 57
Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma
2017 · Mamiko Sakata-Yanagimoto, Rie Nakamoto-Matsubara, et al. · Annals of Hematology · 45
Identification of a novel fusion gene MLL‐MAML2 in secondary acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(q21q23)
2007 · Noriko Nemoto, Kazumi Suzukawa, et al. · Genes Chromosomes and Cancer · 43
PDF
Clinicopathological features and prognostic factors of Japanese patients with “peripheral T-cell lymphoma, unspecified” diagnosed according to the WHO classification
2004 · Hiroshi Kojima, Yuichi Hasegawa, et al. · Leukemia Research · 38
Role of phosphatidylinositol-3 kinase and its association with Gab1 in thrombopoietin-mediated up-regulation of platelet function
2001 · Hiroshi Kojima, Atsushi Shinagawa, et al. · Experimental Hematology · 38
PDF
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations
2020 · Daniel A. Pollyea, Courtney D. Dinardo, et al. · Blood · 37
Quantification of mRNA in Whole Blood by Assessing Recovery of RNA and Efficiency of cDNA Synthesis
2006 · Masato Mitsuhashi, Shigeru Tomozawa, et al. · Clinical Chemistry · 32
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
2018 · Kenshi Suzuki, Meletios A. Dimopoulos, et al. · Blood Cancer Journal · 31
PDF
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia
2011 · Chikashi Yoshida, Takuya Komeno, et al. · International Journal of Hematology · 31
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
2021 · Kazuhito Yamamoto, Atsushi Shinagawa, et al. · Japanese Journal of Clinical Oncology · 29
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
2014 · Naoto Takahashi, Masatomo Miura, et al. · Biomarker Research · 25
PDF
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia
2013 · Takashi Kumagai, Eri Matsuki, et al. · International Journal of Hematology · 24
Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of vonWillebrand factor
2005 · Atsushi Shinagawa, Michael Berndt, et al. · Thrombosis and Haemostasis · 23
Clinicopathological analyses of 5 Japanese patients with CD56+ primary cutaneous lymphomas.
2000 · H Kojima, H Y Mukai, et al. · PubMed · 22
Complex Translocation (6;21;8), a Variant of t(8;21), with Trisomy 4 in a Patient with Acute Myelogenous Leukemia (M2)
1999 · Atsushi Shinagawa, Tsunehiko Komatsu, et al. · Cancer Genetics and Cytogenetics · 19
Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
2016 · Kenshi Suzuki, Atsushi Shinagawa, et al. · Cancer Science · 14
PDF
Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase
2014 · Koiti Inokuchi, Takashi Kumagai, et al. · Journal of the Japan Society of the Reticuloendothelial System · 12
PDF
Megakaryopoiesis in patients with cyclic thrombocytopenia
1995 · Toshiro Nagasawa, Yuichi Hasegawa, et al. · British Journal of Haematology · 12
Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
2017 · Shinsuke Iida, Tatsuo Ichinohe, et al. · International Journal of Hematology · 11
Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis
2016 · Koji Kawamura, Takashi Ikeda, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Ex Vivo Induction of mRNA in Human Whole Blood as a New Platform of Drug and Dietary Supplement Development
2008 · Masato Mitsuhashi, Mieko Ogura, et al. · Pharmaceutical Research · 8
PDF
Quantification of Drug-Induced mRNA in Human Whole Blood ex vivo
2008 · Masato Mitsuhashi, Katsuya Endo, et al. · Clinical Medicine Insights Blood Disorders · 8
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
2023 · Noboru Asada, Jun Ando, et al. · Japanese Journal of Clinical Oncology · 7
PDF
Works count: 78
Citation count: 1,147
H-index: 17
I10-index: 21
Year
Topic
Type